NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $5.00 -0.20 (-3.85%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.08 +0.08 (+1.68%) As of 10/3/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Silence Therapeutics Stock (NASDAQ:SLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silence Therapeutics alerts:Sign Up Key Stats Today's Range$4.90▼$5.2650-Day Range$4.51▼$6.2052-Week Range$1.97▼$20.48Volume75,562 shsAverage Volume66,625 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$32.60Consensus RatingHold Company Overview Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities. The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism. Both programs have advanced through early clinical stages, generating proof-of-concept data. Silence also maintains a portfolio of preclinical research programs targeting liver-related diseases, while exploring strategic collaborations to broaden the reach of its RNAi platform across multiple therapeutic areas. Founded in the United Kingdom and headquartered in London, Silence Therapeutics operates research and development facilities in Europe and the United States. The company has navigated the evolving RNA therapeutics landscape since the early 2000s, transitioning from discovery research into clinical development. Under the leadership of Chief Executive Officer Eric M. Rose, Silence continues to advance its pipeline with the objective of delivering novel RNAi medicines to patients with high-unmet medical needs worldwide.AI Generated. May Contain Errors. Read More Silence Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSLN MarketRank™: Silence Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSilence Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialSilence Therapeutics has a consensus price target of $32.60, representing about 552.0% upside from its current price of $5.00.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Silence Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Silence Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Silence Therapeutics has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Silence Therapeutics has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for SLN on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLN Stock News HeadlinesSilence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comSilence Therapeutics to Participate in September Investor ConferencesSeptember 2, 2025 | businesswire.comTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.October 5 at 2:00 AM | Stansberry Research (Ad)Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | businesswire.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSee More Headlines SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $6.88 on January 1st, 2025. Since then, SLN shares have decreased by 27.3% and is now trading at $5.00. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) posted its earnings results on Thursday, August, 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.27. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $8.50 million. Silence Therapeutics had a negative net margin of 294.20% and a negative trailing twelve-month return on equity of 67.48%. How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/07/2025Today10/05/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLN CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees100Year Founded1999Price Target and Rating Average Price Target for Silence Therapeutics$32.60 High Price Target$75.00 Low Price Target$3.00 Potential Upside/Downside+552.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.31 million Net Margins-294.20% Pretax Margin-291.12% Return on Equity-67.48% Return on Assets-40.47% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual Sales$43.26 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book1.12Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.39 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SLN) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.